News Releases

- Virtual event to be held on Tuesday, April 7, 2020 at 8:00 a.m. ET - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 25, 2020-- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CX...

– Pivotal Phase 3 clinical trial of lead candidate mavorixafor in WHIM syndrome ongoing with top-line results expected in the second half of 2021 – – Initial Phase 1b results in ongoing Waldenström’s macroglobulinemia (WM) and Severe Congenital Neutropenia (SCN) trials expected i...

CAMBRIDGE, Mass. --(BUSINESS WIRE)-- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced that, on February 28, 2020 , the Compensation Committee of...

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 27, 2020-- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced it will host a conference call and webcast ...

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 25, 2020-- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced that the management team will present and c...

– Patent expected to provide exclusivity through 2038 – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 12, 2020-- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, tod...

– Trial to assess safety and tolerability of mavorixafor in combination with ibrutinib in WM patients with MYD88/CXCR4 double mutation associated with treatment resistance – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 30, 2019-- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-st...

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 26, 2019-- X4 Pharmaceuticals, Inc. (Nasdaq:XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced that, on November 26, 2019 , the Compensatio...

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 26, 2019-- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the research, development and commercialization of novel therapeutics for the treatment of rare diseases, announced today the pricing...

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 25, 2019-- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the research, development and commercialization of novel therapeutics for the treatment of rare diseases, announced today that it has...

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 15, 2019-- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced that management will present at the Stifel ...

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 12, 2019-- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration ...

Received orphan drug designation from the European Commission for mavorixafor for treatment of WHIM Syndrome Reported positive data from Phase 2a clinical trial of mavorixafor in combination with axitinib in advanced clear cell renal cell carcinoma patients Hosts investment commu...

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 5, 2019-- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced the initiation of a Phase 1b clinical trial ...

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 4, 2019-- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced the appointment of Derek Meisner , J.D., as ...

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 25, 2019-- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced that it will report its financial results f...

  Subgroup exceeds target of 50% improvement in median progression-free survival     12% of patients remain on combination treatment with durations of 17 months or longer     Hosts investor conference call and webcast on Monday, September 30 at 8:00 AM EDT / 2:00 PM CEST     BARC...

  CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 27, 2019-- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced that, on September 27, 2019 , the Compens...

  CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 23, 2019-- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced the appointment of William “Bill” E....

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 18, 2019-- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced the appointment of Renato Skerlj , Ph.D., a...